- Home
- SPXX vs CDXS Comparison
SPXX vs CDXS Comparison
Compare SPXX & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPXX
- CDXS
- Stock Information
- Founded
- SPXX 2004
- CDXS 2002
- Country
- SPXX United States
- CDXS United States
- Employees
- SPXX N/A
- CDXS N/A
- Industry
- SPXX Trusts Except Educational Religious and Charitable
- CDXS Major Chemicals
- Sector
- SPXX Finance
- CDXS Industrials
- Exchange
- SPXX Nasdaq
- CDXS Nasdaq
- Market Cap
- SPXX 329.9M
- CDXS 361.3M
- IPO Year
- SPXX N/A
- CDXS 2010
- Fundamental
- Price
- SPXX $18.22
- CDXS $4.18
- Analyst Decision
- SPXX
- CDXS Buy
- Analyst Count
- SPXX 0
- CDXS 2
- Target Price
- SPXX N/A
- CDXS $11.00
- AVG Volume (30 Days)
- SPXX 51.3K
- CDXS 566.1K
- Earning Date
- SPXX 01-01-0001
- CDXS 02-27-2025
- Dividend Yield
- SPXX 7.55%
- CDXS N/A
- EPS Growth
- SPXX N/A
- CDXS N/A
- EPS
- SPXX N/A
- CDXS N/A
- Revenue
- SPXX N/A
- CDXS $64,446,000.00
- Revenue This Year
- SPXX N/A
- CDXS N/A
- Revenue Next Year
- SPXX N/A
- CDXS $2.02
- P/E Ratio
- SPXX N/A
- CDXS N/A
- Revenue Growth
- SPXX N/A
- CDXS N/A
- 52 Week Low
- SPXX $13.57
- CDXS $2.56
- 52 Week High
- SPXX $16.05
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- SPXX 57.57
- CDXS 41.30
- Support Level
- SPXX $18.04
- CDXS $4.14
- Resistance Level
- SPXX $18.49
- CDXS $4.41
- Average True Range (ATR)
- SPXX 0.15
- CDXS 0.22
- MACD
- SPXX 0.00
- CDXS 0.01
- Stochastic Oscillator
- SPXX 63.01
- CDXS 38.89
About SPXX Nuveen S&P 500 Dynamic Overwrite Fund
Nuveen S&P 500 Dynamic Overwrite Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total returns with less volatility than the S&P 500 Index by investing in a U.S. equity portfolio that seeks to substantially replicate the price movements of the S&P 500 Index, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio (with a 55% long-term target) in an effort to enhance the Fund's risk-adjusted returns.
About CDXS Codexis Inc.
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.